Shots:
- The EC has approved Pfizer‘s Hympavzi (marstacimab; QW, SC) for the treatment of pts (≥12yrs., ≥35kg) with hemophilia A with FVIII inhibitors or hemophilia B with FIX inhibitors, based on P-III (BASIS) study
- During the active treatment period, Hympavzi achieved a 93% reduction in mean treated ABR vs on-demand therapy (1.39 vs 19.78), plus demonstrated superiority across all bleeding-related 2EPs; mean & median treated ABRs remained low for an additional 43mos. OLE period
- Additionally, the US FDA has granted priority review to Hympavzi for the treatment of pts (≥6yrs.) with hemophilia A or B with inhibitors, & in pts (6-11yrs.) with hemophilia A or B without inhibitors (PDUFA: Q2’26)
Ref: Businesswire | Image: Pfizer | Press Release
Related News: Arvinas and Pfizer Report the US FDA Approval of Veppanu (Vepdegestrant) for ESR1-Mutated Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
